818PPost hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI